Hormonal
Chronic activation of AMP-activated protein kinase (AMPK) via AICAR remodels white adipose tissue metabolism to promote energy dissipation by upregulating fatty acid oxidation genes (PGC-1α, PPARα, PPARδ) and increasing Adipose Triglyceride Lipase (ATGL) content, while simultaneously suppressing Hormone-Sensitive Lipase (HSL) activity.
This research suggests that chronically stimulating the cellular energy sensor AMPK (using the drug AICAR in this study) can reprogram fat cells to burn more fat and store less, primarily by increasing the amount of a specific fat-burning enzyme (ATGL). However, this effect is not immediate and involves a complex interplay where another fat-burning enzyme (HSL) is actually suppressed. This highlights that simply 'activating' energy sensors is not a simple on/off switch for fat loss and may have delayed or counter-intuitive initial effects.
Here, we provide evidence that prolonged AICAR-induced AMPK activation can remodel adipocyte metabolism by upregulating pathways that favor energy dissipation versus lipid storage in WAT. Additionally, we show novel time-dependent effects of AICAR-induced AMPK activation on lipolysis, which involves antagonistic modulation of HSL and ATGL.
Why this rating
The study uses both in vitro and in vivo models with rigorous controls, multiple assays, and statistical significance, though it relies on a pharmacological activator (AICAR) rather than a natural physiological state.
Source
Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL
Mandeep P. Gaidhu et al. · Journal of Lipid Research · 2008
DOI 10.1194/jlr.m800480-jlr200
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →